New evidence indicates vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality risk
Philadelphia | September 19, 2023
Study published in the Journal of Investigative Dermatology offers new avenues for research and insights into mechanisms underlying this protective effect
According to a new study comparing patients with and without vitiligo in South Korea, patients with vitiligo were associated with a 25% decreased risk of mortality compared with controls. This suggests that vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality. The results(opens in new tab/window) appear in the Journal of Investigative Dermatology(opens in new tab/window), published by Elsevier.
Previous studies have documented a reduced risk of cancer in patients with vitiligo, however, there has been limited research on the relationship between vitiligo-associated autoimmunity and the risk of morbidity and mortality among patients with vitiligo.
Lead investigator Jung Min Bae, MD, PhD, Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, explains: "As a clinician, one of my goals is to conduct research that can encourage my patients with vitiligo. It was interesting to find that immunotherapy used in cancer treatment often induces autoimmune side-effects like vitiligo. My colleagues and I hypothesized that vitiligo, which is an autoimmune disorder, could have a protective effect against cancer. Our research shows that patients with vitiligo were associated with a 25% decreased risk of mortality compared to the controls, suggesting that vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality."
The mortality of patients with vitiligo was investigated in a population-based cohort using the National Health Insurance Service (NHIS) database and the National Death Registry in South Korea. All-cause and cause-specific mortality were compared between patients with vitiligo and controls. In total, 107,424 patients with incident vitiligo and 537,120 matched controls were included. The mortality rates were 34.8 and 45.3 per 10,000 person-years in patients and controls, respectively. In addition to cancer, other cause-specific mortality including infectious diseases, hematologic diseases, endocrine diseases, neurologic diseases, cardiovascular diseases, respiratory diseases, and renal/urogenital disease was lower in patients with vitiligo.
Caption: A new study published in the Journal of Investigative Dermatology has determined that patients with vitiligo were associated with a lower risk of mortality, suggesting that vitiligo-associated autoimmunity may contribute to reduced morbidity and mortality (Credit: iStock.com/FG Trade).
According to co-lead investigator Solam Lee, MD, PhD, Department of Dermatology, Yonsei University Wonju College of Medicine: "The strength of our study is the utilization of the large NHIS database, which provides comprehensive information about patient BMI, lifestyles, comorbidities, laboratory findings, and linkage with death certificates. The study employed various statistical methods to reduce the potential bias, which makes the results more robust."
Whether these findings are attributable to the autoimmune mechanism of vitiligo itself or to unexpected effects of vitiligo treatment modalities (e.g., phototherapy) remains to be clarified in future studies.
First author Hyun Jeong Ju, MD, PhD, Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, adds: "Our findings are significant because they suggest that the autoimmune nature of vitiligo may confer certain protective effects against various causes of mortality, and they offer new avenues for research into the mechanisms underlying this protective effect. Moreover, understanding the mortality risk in patients with vitiligo will lead to improved patient counseling, health monitoring, and overall management strategies for patients."
Vitiligo is a chronic skin disorder characterized by depigmented patches; worldwide prevalence is estimated at 0.5-2% of the general population. Multiple factors contribute to the pathogenesis of vitiligo including susceptibility to oxidative stress, functional abnormalities of melanocytes, adhesion defect between melanocytes and keratinocytes, and autoreactive cytotoxic T cells.
Notes for editors
The article is “All-cause and cause-specific mortality among patients with vitiligo: A nationwide population-based study in Korea,” by Hyun Jeong Ju, Hyun Kang, Ju Hee Han, Ji Hae Lee, Solam Lee, and Jung Min Bae (https://doi.org/10.1016/j.jid.2023.07.007(opens in new tab/window)). It appears online in the Journal of Investigative Dermatology, published by Elsevier.
The article is openly available at https://www.jidonline.org/article/S0022-202X(23)02481-8/fulltext(opens in new tab/window).
Full text of the article is also available to credentialed journalists upon request. Contact Theresa Monturano, at +1 215 239 3711 or [email protected](opens in new tab/window) to request a PDF of the article. Journalists wishing to interview the authors should contact Jung Min Bae, MD, PhD, at [email protected](opens in new tab/window).
About Journal of Investigative Dermatology
The Journal of Investigative Dermatology(opens in new tab/window) (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high-impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.org(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.